Mohammad Amin Shahrbaf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohammad Amin Shahrbaf has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
DanialSamiei Nasr
Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication- Masoumeh Nouri
Research and Development Department, Royan Stem Cell Technology Company, Tehran, Iran
1 shared publication - Massoud Vosough
Royan Institute for Stem Cell Biology and Technology, ACECR
1 shared publication - Morteza Zarrabi
Research and Development Department, Royan Stem Cell Technology Company, Tehran, Iran
1 shared publication - Roberto Gramignoli
Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden
1 shared publication ZoyaTavaf Langroudi
Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- Open Access
- 5 October 2022
- Published by Medknow in International Journal of Preventive Medicine
- Vol. 13 (1) , 125
COVID-19 and health promoting hospitals in Iran; What do we stand?
- 5 October 2022
- Published by Medknow in International Journal of Preventive Medicine
- Vol. 13 (1) , 125
Open AccessCOVID-19 and health promoting hospitals in Iran; What do we stand?
- Open Access
Extraembryonic Mesenchymal Stromal/Stem Cells in Liver Diseases: A Critical Revision of Promising Advanced Therapy Medicinal Products
Liver disorders have been increasing globally in recent years. These diseases are associated with high morbidity and mortality rates and impose high care costs on the health system. Acute liver failure, chronic and congenital liver diseases, as well as hepatocellular carcinoma have been limitedly treated by whole organ transplantation so far. But novel treatments for liver disorders using cell-based approaches have emerged in recent years. Extra-embryonic tissues, including umbilical cord, amnion membrane, and chorion plate, contain multipotent stem cells. The pre-sent manuscript discusses potential application of extraembryonic mesenchymal stromal/stem cells, focusing on the management of liver diseases. Extra-embryonic MSC are characterized by robust and constitutive anti-inflammatory and anti-fibrotic properties, indicating as therapeutic agents for inflammatory conditions such as liver fibrosis or advanced cirrhosis, as well as chronic inflammatory settings or deranged immune responses.
Open AccessExtraembryonic Mesenchymal Stromal/Stem Cells in Liver Diseases: A Critical Revision of Promising Advanced Therapy Medicinal Products
Liver disorders have been increasing globally in recent years. These diseases are associated with high morbidity and mortality rates and impose high care costs on the health system. Acute liver failure, chronic and congenital liver diseases, as well as hepatocellular carcinoma have been limitedly treated by whole organ transplantation so far. But novel treatments for liver disorders using cell-based approaches have emerged in recent years. Extra-embryonic tissues, including umbilical cord, amnion membrane, and chorion plate, contain multipotent stem cells. The pre-sent manuscript discusses potential application of extraembryonic mesenchymal stromal/stem cells, focusing on the management of liver diseases. Extra-embryonic MSC are characterized by robust and constitutive anti-inflammatory and anti-fibrotic properties, indicating as therapeutic agents for inflammatory conditions such as liver fibrosis or advanced cirrhosis, as well as chronic inflammatory settings or deranged immune responses.